FDA ap­proves Tai­ho's Lon­surf with be­va­cizum­ab for metasta­t­ic col­orec­tal can­cer

The FDA on Wednes­day ap­proved Tai­ho On­col­o­gy’s Lon­surf (tri­fluri­dine and tipiracil) with be­va­cizum­ab for metasta­t­ic col­orec­tal can­cer (mCRC) in those who were pre­vi­ous­ly treat­ed with flu­o­ropy­rim­i­dine-, ox­ali­platin- and irinote­can-based chemother­a­py, an an­ti-VEGF bi­o­log­i­cal ther­a­py, and if RAS wild-type, an an­ti-EGFR ther­a­py.

The ap­proval, which came 11 days ahead of its PDU­FA date, comes al­most eight years af­ter the agency ap­proved sin­gle-agent Lon­surf for the same in­di­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER